To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1∗28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1∗28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1∗28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1∗28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1∗28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1∗28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.